Skip to main content

Advertisement

Log in

The Role of Radiation in the Perioperative Treatment of Esophagogastric Cancer

  • Esophageal and Gastric Cancer
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 22 February 2011

Opinion statement

Cancers of the esophagus, stomach, and the esophagogastric junction (EGJ) remain a global health problem. There has been a dramatic increase in the incidence of adenocarcinoma of the distal esophagus and EGJ in the past two decades with little change in the poor prognosis associated with these cancers. Previously surgery alone was the mainstay of therapeutic intervention, but high rates of local and systemic failure have prompted investigation into neoadjuvant and adjuvant therapy. Treatment paradigms differ across continents, but the unifying theme that has emerged in the past decade implies that surgery alone can no longer be considered the standard of care. The multi-disciplinary management of patients with locally advanced esophagogastric carcinomas using trimodality therapy with radiotherapy, chemotherapy, and surgery confers the greatest opportunity for margin negative resection, improved loco-regional control and cure, and should be the accepted treatment paradigm. The traditional backbone of platinum plus fluorouracil concurrent with radiotherapy may be supplanted by more modern, easier-to-administer regimens incorporating taxanes and irinotecan. The current generation of clinical trials in this heterogeneous group of diseases is examining targeted therapy, newer methods of radiotherapy, and predictors of response to therapy aiming to tailor management to an individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance. ••Of major importance

  1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010, 60:277–300.

    Article  PubMed  Google Scholar 

  2. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049–2053.

    Article  CAS  PubMed  Google Scholar 

  3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287–1289.

    Article  CAS  PubMed  Google Scholar 

  4. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74–108.

    Article  PubMed  Google Scholar 

  5. Tepper JE: Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? Gastrointest Cancer Res 2008, 2:S2–S5.

    PubMed  Google Scholar 

  6. Edge SB, Byrd DR, Compton CC, et al.: AJCC Cancer staging handbook: from the AJCC cancer staging manual7th. New York: Springer; 2010:

    Google Scholar 

  7. Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85:1457–1459.

    Article  CAS  PubMed  Google Scholar 

  8. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005, 90:139–146. (discussion 146).

    Article  PubMed  Google Scholar 

  9. Aikou T, Shimazu H: Difference in main lymphatic pathways from the lower esophagus and gastric cardia. Jpn J Surg 1989, 19:290–295.

    Article  CAS  PubMed  Google Scholar 

  10. Tachimori Y, Kato H, Watanabe H, et al.: Difference between carcinoma of the lower esophagus and the cardia. World J Surg 1996, 20:507–510. (discussion 511).

    Article  CAS  PubMed  Google Scholar 

  11. Smalley SR, Gunderson L, Tepper J et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002; 52: 283-293

    Google Scholar 

This paper is a consensus statement on the role of radiotherapy and provides guidance on specific treatment considerations, recommendations for field definitions and highlights important anatomic issues.

  1. Matzinger O, Gerber E, Bernstein Z, et al.: EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009, 92:164–175.

    Article  PubMed  Google Scholar 

Excellent consensus guidelines on target volume delineation and critical anatomic considerations for radiation treatment planning.

  1. Rudiger Siewert J, Feith M, Werner M, Stein HJ: Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1, 002 consecutive patients. Ann Surg 2000, 232:353–361.

    Article  CAS  PubMed  Google Scholar 

  2. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462–467.

    Article  CAS  PubMed  Google Scholar 

  3. Kelsen DP, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979–1984.

    Article  CAS  PubMed  Google Scholar 

  4. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305–313.

    CAS  PubMed  Google Scholar 

  5. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730.

    Article  CAS  PubMed  Google Scholar 

  6. MRCOCW Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727–1733.

    Article  Google Scholar 

  7. Burmeister BH, Smithers BM, Gebski V, et al.: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659–668.

    Article  PubMed  Google Scholar 

  8. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11–20.

    Article  CAS  PubMed  Google Scholar 

  9. Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol (Meeting Abstracts) 2007, 25:4510.

    Google Scholar 

  10. Tepper J, Krasna MJ, Niedzwiecki D, et al.: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086–1092.

    Article  CAS  PubMed  Google Scholar 

Relevant phase III trial demonstrating the benefit of trimodality therapy versus surgery alone despite poor accrual and early closure.

  1. Allum WH, Stenning SP, Bancewicz J, et al.: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062–5067.

    Article  PubMed  Google Scholar 

  2. Herskovic A, Martz K, al-Sarraf M, et al.: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593–1598.

    Article  CAS  PubMed  Google Scholar 

  3. al-Sarraf M, Martz K, Herskovic A, et al.: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997, 15:277–284.

    CAS  PubMed  Google Scholar 

  4. Cooper JS, Guo MD, Herskovic A, et al.: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623–1627.

    Article  CAS  PubMed  Google Scholar 

  5. Minsky BD, Pajak TF, Ginsberg RJ, et al.: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167–1174.

    Article  CAS  PubMed  Google Scholar 

  6. Kelsen DP, Winter KA, Gunderson LL, et al.: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719–3725.

    Article  PubMed  Google Scholar 

  7. Gaast AV, van Hagen P, Hulshof M, et al.: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol (Meeting Abstracts) 2010, 28:4004.

    Google Scholar 

Recent abstract presentation at the 2010 ASCO meeting demonstrating the superiority of carboplatin plus paclitaxel-based neoadjuvant chemoradiation plus surgery versus surgery in a randomized phase III setting. These results will likely change practice patterns in terms of type of chemotherapy used with radiation.

  1. Khushalani NI, Leichman CG, Proulx G, et al.: Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002, 20:2844–2850.

    Article  CAS  PubMed  Google Scholar 

  2. Javle MM, Yang G, Nwogu CE, et al.: Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 2009, 27:193–200.

    Article  CAS  PubMed  Google Scholar 

  3. Khushalani NI, Yang G, Tan W, et al.: Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). J Clin Oncol (Meeting Abstracts) 2010, 28:4100.

    Google Scholar 

  4. Kleinberg L, Powell ME, Forastiere AA, et al.: Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol (Meeting Abstracts) 2008, 26:4532.

    Google Scholar 

  5. Sharma R, Yang GY, Nava HR, et al.: A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). J Clin Oncol (Meeting Abstracts) 2009, 27:15619.

    Google Scholar 

  6. Gebski V, Burmeister B, Smithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226–234.

    Article  CAS  PubMed  Google Scholar 

Meta-analysis demonstrating the benefit of neoadjuvant chemotherapy and chemoradiotherapy in the treatment of esophageal carcinoma

  1. Coburn NG, Govindarajan A, Law CHL, et al.: Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4, 041 patients. Ann Surg Oncol 2008, 15:500–507.

    Article  PubMed  Google Scholar 

  2. Fiorica F, Cartei F, Enea M, et al.: The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007, 33:729–740.

    Article  PubMed  Google Scholar 

  3. Stahl M, Walz MK, Stuschke M, et al.: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851–856.

    Article  CAS  PubMed  Google Scholar 

Relevant trial evaluating induction chemotherapy versus chemoradiotherapy in the preoperative management of esophagus cancer.

  1. Berger AC, Farma J, Scott WJ, et al.: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005, 23:4330–4337.

    Article  PubMed  Google Scholar 

  2. Rohatgi P, Swisher SG, Correa AM, et al.: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005, 104:2365–2372.

    Article  PubMed  Google Scholar 

  3. Lagarde SM, ten Kate FJW, Reitsma JB, et al.: Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2006, 24:4347–4355.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nikhil I. Khushalani MD.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11864-011-0143-7

Rights and permissions

Reprints and permissions

About this article

Cite this article

May, K.S., Yang, G.Y. & Khushalani, N.I. The Role of Radiation in the Perioperative Treatment of Esophagogastric Cancer. Curr. Treat. Options in Oncol. 12, 61–71 (2011). https://doi.org/10.1007/s11864-011-0139-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0139-3

Keywords

Navigation